Metabolic syndrome is a cluster of conditions — high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol — that together raise the risk of heart disease, stroke, and type 2 diabetes. About one in three U.S. adults meets the criteria. Treatment traditionally focuses on weight loss, physical activity, and medications that address each component separately.
What's actually going on in research
Trials are testing GLP-1 receptor agonists like semaglutide and tirzepatide that target multiple metabolic factors at once, drugs that improve insulin sensitivity without weight gain, and approaches aimed at inflammation and fat distribution. Researchers are also studying how the microbiome, sleep disruption, and early-life exposures contribute to metabolic risk.
GLP-1 and dual agonists
Drugs like semaglutide and tirzepatide produce sustained weight loss and improve blood pressure, blood sugar, and cholesterol simultaneously. Trials are now testing whether they reduce heart attacks and strokes in people with metabolic syndrome.
Targeting inflammation
Several studies are testing whether anti-inflammatory drugs can reduce cardiovascular risk in people with metabolic syndrome. Early results suggest that lowering inflammation may help even when cholesterol is controlled.
Liver fat reduction
New drugs targeting fatty liver disease aim to reverse fat buildup that often drives insulin resistance. Some work by blocking fat production in the liver, others by improving how the body burns fat.
What to know before you search
Eligibility typically depends on meeting criteria for metabolic syndrome (usually three of five factors: waist size, blood pressure, blood sugar, triglycerides, HDL cholesterol), sometimes with additional requirements around BMI or fatty liver disease.
What types of trials are currently open
- Weight loss trials — Testing GLP-1 drugs, dual agonists, and other medications to see how much weight they produce and whether metabolic improvements persist long-term.
- Cardiovascular outcome trials — Following people with metabolic syndrome for years to see if new treatments reduce heart attacks, strokes, and death.
- Diabetes prevention trials — Testing whether medications or lifestyle programs can prevent progression from prediabetes to type 2 diabetes in people with metabolic syndrome.
- Fatty liver trials — Testing drugs that reduce liver fat and inflammation in people with metabolic syndrome and non-alcoholic fatty liver disease.
- Lifestyle intervention studies — Comparing different approaches to diet, exercise, and behavior change to find what produces lasting metabolic improvement.
Recently added Metabolic Syndrome trials
Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID
This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long COVID. All patients will also be provided with with Dietary \& Lifestyle recommendations specifically designed to enhance immune system function and reduce viral proliferation. Patients will be assessed in the clinic at screening/baseline, 3 and 6 weeks while on treatment, and by telephone at 4 weeks post-treatment. All patients will be asked to fill in a diary to record their daily treatment dosage when being treated with PNMR + SOC or with SOC alone. Primary objective: To evaluate the efficacy of PNMR + (SOC) vs. SOC in the treatment and management of patients with long COVID.
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.
Find Metabolic Syndrome trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.